This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
CAH Gains More Than 29% in 4 Months: Will the Uptrend Continue?
by Indrajit Bandyopadhyay
Cardinal Health's 29% rally reflects stronger specialty growth, MSO expansion and higher-margin assets, but cost pressures could test the uptrend.
CAHNegative Net Change MCKNegative Net Change CORNegative Net Change
medical medical-devices
Revvity to Acquire Human Cell Design to Boost Metabolic Discovery
by Zacks Equity Research
RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.
RVTYPositive Net Change WSTNegative Net Change GMEDPositive Net Change VCYTNegative Net Change
medical medical-devices
IceCure Secures China NMPA Approval for ProSense Cryoablation System
by Zacks Equity Research
ICCM's NMPA approval for ProSense opens China to commercialization, expanding its global regulatory footprint and long-term revenue opportunity.
ICCMNo Net Change WSTNegative Net Change GMEDPositive Net Change VCYTNegative Net Change
medical medical-devices
New Strong Buy Stocks for September 11th
by Zacks Equity Research
RCMT, HCSG, BLMN, AGX and GMED have been added to the Zacks Rank #1 (Strong Buy) List on September 11, 2026.
BLMNNegative Net Change AGXPositive Net Change GMEDPositive Net Change HCSGPositive Net Change RCMTNegative Net Change
business-services construction medical-devices restaurants
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
by Zacks Equity Research
ECL benefits from high-tech growth, digital expansion, innovation and solid Q2 results, while cost fluctuations remain a key concern.
ECLPositive Net Change WSTNegative Net Change GMEDPositive Net Change VCYTNegative Net Change
medical medical-devices
COO Q3 Earnings Top Estimates, Revenues Miss on Destocking, Stock Down
by Zacks Equity Research
Cooper Companies' Q3 EPS beats estimates as expense controls offset softer revenues, while U.S. inventory cuts pressure CooperVision and weigh on shares.
COONo Net Change WSTNegative Net Change GMEDPositive Net Change VCYTNegative Net Change
earnings medical medical-devices
Do Options Traders Know Something About AtriCure Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
ATRCNegative Net Change
medical medical-devices
Pre-Markets in Red on Higher Crude Oil Prices and U.S. Bond Yields
by Zacks Equity Research
U.S. stock futures are in negative territory after three days of decline.
MPositive Net Change AEOPositive Net Change COONo Net Change AVAVNegative Net Change
aerospace medical-devices retail
Is This the Right Time to Add Neogen Stock to Your Portfolio?
by Zacks Equity Research
NEOG advances product innovation and recovers Animal Safety operations, but high debt and intense competition remain key risks.
NEOGPositive Net Change TFXPositive Net Change GMEDPositive Net Change VCYTNegative Net Change
medical medical-devices
BTSG's Specialty Pharmacy Sales Up 30%: Will the Growth Continue?
by Indrajit Bandyopadhyay
BrightSpring Health Services' Specialty and Infusion sales rose 30%, backed by LDD growth, new launches and expansion into rare therapies.
BTSGPositive Net Change HUMPositive Net Change CIPositive Net Change
medical medical-devices